Aurobindo Pharma Announces 39th AGM on Aug 27, 2026, via VC/OAVM
Aurobindo Pharma Limited will hold its 39th AGM on August 27, 2026, via Video Conferencing. Remote e-voting is open from August 24 to August 26, 2026. The cut-off date for voting eligibility is August 20, 2026. The Register of Members will be closed from August 26-27, 2026.
This is a standard procedural announcement about the AGM and does not involve any new business developments, financial results, or strategic changes that would have a material impact on the company's stock price.
The announcement is a routine corporate communication regarding the Annual General Meeting and does not contain any financial or operational information that would significantly impact the company's stock.
Aurobindo Pharma Limited has announced that its 39th Annual General Meeting (AGM) will be held on Thursday, August 27, 2026, at 3:30 p.m. IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio Visual Means (OAVM), in compliance with applicable provisions of the Companies Act, 2013, SEBI Listing Regulations, and relevant circulars from the Ministry of Corporate Affairs and SEBI.
The Notice of the AGM and the Annual Report for the financial year 2025-26 have been dispatched via email to members whose email addresses are registered with the Company, RTA, or Depository Participants. For shareholders who have not registered their email IDs, a letter with a weblink and QR code for the Integrated Annual Report was dispatched on August 3, 2026.
Members can attend the AGM virtually via VC/OAVM or view a live webcast. Remote e-voting will commence on Monday, August 24, 2026, at 9:00 a.m. IST and conclude on Wednesday, August 26, 2026, at 5:00 p.m. IST. The cut-off date for determining eligibility to vote is Thursday, August 20, 2026. An Insta Poll facility will also be available during the AGM for members who have not cast their votes remotely.
The Register of Members and share transfer books of the Company will remain closed from August 26, 2026, to August 27, 2026, inclusive, for the AGM.
What to do with a filing like this
Aurobindo Pharma Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aurobindo Pharma Limited. Read the original for the full detail.